Intradermal injection of PPD as a novel approach of immunotherapy in anogenital warts in pregnant women

Dermatologic Therapy

Volumn 24, Issue 1, 2011, Pages 137-143

  Eassa, Bayoumy I ^a   Abou Bakr, Amany A ^b   El Khalawany, Mohamed A ^a  

^a AL AZHAR UNIVERSITY   (Egypt)

^b NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

anogenital warts; immunotherapy; PPD

Indexed keywords

TUBERCULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONDYLOMA ACUMINATUM; DRUG EFFICACY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOTHERAPY; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; TREATMENT RESPONSE; TUBERCULIN TEST; VIRUS TYPING;

ADULT; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; PAPILLOMAVIRIDAE; PREGNANCY; TREATMENT OUTCOME; TUBERCULIN; YOUNG ADULT;

EID: 79551513271     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2010.01388.x     Document Type: Article

References (40)

1. Stern R, Johnson M, DeLozier J,. Utilization of physician services for dermatologic complaints. Arch Dermatol 1977: 113: 1062-1066.
2. Kilkenny M, Marks R,. The descriptive epidemiology of warts in the community. Aust J Dermatol 1996: 37: 80-86.
3. De Villier EM, Fauquet C, Broker TR, Benard HU, zur Hausen H,. Classification of papillomaviruses. Virology 2004: 324: 17-27.
4. Cuzick J, Szarewski A, Terry G, et al. Human papillomavirus testing in primary cervical screening. Lancet 1995: 345: 1533-1536.
5. Pre'tet JL, Charlot JF, Mouqin C,. Virology and carcinogenic aspects of HPV. Bull Acad Natl Med 2007: 191: 611-623.
6. Pfister H, Fuchs PG, Majewski S, Jablonska S, Pniewska I, Maleiczyk M,. High prevalence of epidermodysplasia verruciformis associated HPV-DNA in actinic keratosis of immunocompetent population. Arch Dermatol Res 2003: 295: 273-279.
7. Aubin F, Laurent R,. Human papillomavirus associated cutaneous lesion. Rev Prat 2006: 56: 1905-1913.
8. Bunney MH,. Viral warts: their biology and treatment. Oxford: Oxford University press, 1984.
9. Oriel JD,. Natural history of genital warts. Br J Vener Dis 1971: 47: 1-13.
10. Chuang T-Y, Perry HO, Kurland LT, et al. Condyloma acuminatum in Rochester, Minn., 1950-1978. 1. Epidemiology and clinical features. Arch Dermatol 1984: 120: 469-475.
11. Shah K, Kashima H, Polk BF, et al. Rarity of caesarean delivery in cases of juvenile-onset respiratory papillomatosis. Obstet Gynecol 1986: 68: 795-799.
12. Ouerhani R, Juini H, Skhiri A, et al. Condylomata acuminata during pregnancy. Report of 15 cases. Tunis Med 2006: 84: 745-746.
13. Diõgenes MA, Barroso MG,. Experiencing pregnancy with human papillomavirus: a case study. Rev Gaucha Enferm 2007: 28: 340-349.
14. Karowicz-BiliÅska A,. The latent infection of human papilloma virus in pregnant woman and colonization of placenta-preliminary report. Ginekol Pol 2007: 78: 966-970.
15. Gomez LM, Ma Y, Ho C, McGrath CM, Nelson DB, Parry S,. Placental infection with human papillomavirus is associated with spontaneous preterm delivery. Hum Reprod 2008: 23: 709-715.
16. Horn TD, Johnson SM, Helm RM, Roberson PK,. Intralesional immunotherapy of warts with mumps, candida, and trichophyton skin test Antigens. Arch Dermatol 2005: 141: 589-594.
17. Scott M, Nakagawa M, Moscicki AB,. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001: 8: 209-220.
18. Quan MB, Moy RL,. The role of human papillomavirus in carcinoma. J Am Acad Dermatol 1991: 25: 698-705.
19. Majewski S, Jablonska S,. Immunology of HPV infection and HPV-associated tumors. Int J Dermatol 1998: 37: 81-95.
20. Kus S, Ergun D, Akin O,. Intralesional tuberculin for treatment of refractory warts. J Eur Acad Dermatol Venereol 2005: 19: 503-523.
21. McEvoy GK, ed. AHFS drug information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994: 1631-1636.
22. Fine PEM, Carneiro IAM, Milstein JB, Clements CJ,. Issues relating to the use of BCG in immunization programs. Geneva: WHO, 1999.
23. Sambrook J, Fritsch EF, Maniatis T,. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989: 9.16-9.23.
24. Jacobs M, De Roda Husman A, Van den Brule A, Snijders P, Meijer C, Walboomers J,. Group specific differentiation between high- and low-risk human papillomavirus genotypes by general primer mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 1995: 33: 901-905.
25. Tendler Y, Schwartz Y, Reshef R, Shasha SM, Rotter V, Shkolnik T,. Immunohistochemical detection of p53 protein expression in HPV-induced condyloma acuminatum. Acta Derm Venereol 1995: 75: 177-179.
26. Moscicki AB,. Impact of HPV infection in adolescent populations. J Adolesc Health 2005: 37 (6 Suppl.): S3-S9.
27. Daneshpouy M, Soce G, Clavel C, et al. Human papillomavirus infection and anogenital condyloma in bone marrow transplant recipients. Transplantation 2001: 71: 167-169.
28. Johnson SM, Roberson PK, Horn TD,. Intralesional injection of mumps or candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol 2001: 137: 451-455.
29. Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1995: 44 (RR-11): 19-34.
30. Almeida Goncalves JC,. 5-Fluorouracil in the treatment of common warts of the hands. Br J Dermatol 1975: 92: 89-91.
31. Mario M,. Imiquimod 5% cream: a topical immune response modifier. Int J Dermatol 2002: 41 (Suppl. 1): 1-2.
32. Buckley DA, Keane FM, Munn SE, et al. Recalcitrant viral warts treated by diphencyprone immunotherapy. Br J Dermatol 1999: 141: 292-296.
33. Lahti A, Hannuksela M, Topical Immunotherapy with Tuberculin jelly for common warts. Arch Dermatol Res 1983: 273: 153-154.
34. Metawea B, El-nashar A-R, Kamel I, Kassem W, Shamloul R,. Application of viable bacille calmette-guérin topically as a potential therapeutic modality in condylomata acuminata: a placebo-controlled study. Urology 2005: 65: 247-250.
35. Gupta S, Malhotra AK, Sharma VK,. Intralesional immunotherapy with killed Mycobacterium vaccine for the treatment of ano-genital warts: an open labeled pilot study. J Eur Acad Dermatol Venereol 2008: 22: 1089-1093.
36. Bunney M, Nolan M, Williams D,. An assessment of methods of treating viral warts by comparative treatment trials based on a standard design. Br J Dermatol 1976: 94: 667-669.
37. Bourke J, Berth-Jones J, Hutchinson P,. Cryotherapy of common viral warts at intervals of 1, 2 and 3 weeks. Br J Dermatol 1995: 132: 433-436.
38. Clifton M, Johnson S, Roberson P, Kincannon J, Horn T,. Immunotherapy for recalcitrant warts in children using intralesional mumps or Canndida antigens. Pediatr Dermatol 2003: 20: 268-271.
39. Froeschle JE, Ruben FL, Bloh AM,. Immediate hypersensitivity reactions after use of tuberculin skin testing. Clin Infect Dis 2002: 34: 12-13.
40. Chee YC,. Immediate hypersensitivity reactions to tuberculin on skin-prick testing in tuberculosis patients. Singapore Med J 1984: 25: 340-342.